Document is current
Any future updates will be listed below
-
Authors
Pombo-Suárez, Manuel https://orcid.org/0000-0002-2524-4883
Seoane-Mato, Daniel
Díaz-González, Federico https://orcid.org/0000-0002-4139-9295
Sánchez-Alonso, Fernando
Sánchez-Jareño, Marta
Cea-Calvo, Luis
Castrejón, Isabel https://orcid.org/0000-0003-1811-2417
-
Funding
Funding for this research was provided by:
MSD, Spain
- License Information
-
More Information
Article History
Received: 5 October 2022
Accepted: 20 March 2023
First Online: 7 June 2023
Declarations
:
: The study was performed in accordance with Good Pharmacoepidemiology Practice standards and the principles of the Declaration of Helsinki. The registry and its derived studies were approved by participating Clinical Research Ethic Committees. Informed consent, which includes analyses like that presented herein, is signed by all patients prior to inclusion in BIOBADASER.
: Not Applicable.
: Manuel Pombo-Suárez: consulting honorarium from Janssen, MSD and Sanofi; lectures for Janssen, MSD and Novartis. Daniel Seoane-Mato: no conflict of interest. Federico Díaz-González: no conflict of interest. Fernando Sánchez-Alonso: no conflict of interest. Marta Sánchez-Jareño: full-time employee at MSD, Spain. Luis Cea-Calvo: full-time employee at MSD, Spain. Isabel Castrejón: no conflict of interest.
